Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it matter for Humacyte stock? The Acellular Tissue Engineering Vessel of the company based out
![Bitcoin [BTC] Market Plummets Amid Mt. Gox and German Government Sell-Offs; Justin Sun Offers Rescue](https://resources.cryptocompare.com/news/77/30434164.jpeg "Bitcoin [BTC] Market Plummets Amid Mt. Gox and German Government Sell-Offs; Justin Sun Offers Rescue")
